Longeveron Shares Jumped Another 10% in Morning Trading

Tiger Newspress2022-04-01

Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.

Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.

The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.

Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.

The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.

“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.

In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Gneiss
2022-04-05
Gneiss
Great news!
Mm101
2022-04-05
Mm101
Ff
Lakse
2022-04-02
Lakse
👍👍 long way to go but Good for Alzheimer patients
fhho32
2022-04-02
fhho32
Ok
BenjiFuji
2022-04-01
BenjiFuji
Still a long way to go after phase 1...

Leave a comment

19

180

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126755850?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-01 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126755850","market":"us","top_or_hot":-1,"title":"Longeveron Shares Jumped Another 10% in Morning Trading","media":"Tiger Newspress","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n2022-04-01 21:43 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGVN","symbol_name":"Longeveron Inc","start_time":0,"source_url":"","article_id":"1126755850","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","pubTimestamp":1648820604,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGVN":"Longeveron Inc"},"translate_title":"在早盘交易中，Longeveron的股价又上涨了10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGVN":0.9},"content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9016959602,"gmtCreate":1649120478173,"gmtModify":1676534454867,"author":{"id":"4101868132463050","authorId":"4101868132463050","name":"Gneiss","avatar":"https://static.tigerbbs.com/04e6942e7cce10823f5ef0af66f4c932","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Great news!","listText":"Great news!","text":"Great news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016959602","repostId":1126755850,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9018757164,"gmtCreate":1649108006573,"gmtModify":1676534449861,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ff","listText":"Ff","text":"Ff","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9018757164","repostId":1126755850,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011601666,"gmtCreate":1648858911493,"gmtModify":1676534411328,"author":{"id":"4099488158821640","authorId":"4099488158821640","name":"Lakse","avatar":"https://static.tigerbbs.com/9917c89f79766bda212d6a8e45307c1c","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"👍👍 long way to go but&nbsp;Good for Alzheimer patients","listText":"👍👍 long way to go but&nbsp;Good for Alzheimer patients","text":"👍👍 long way to go but Good for Alzheimer patients","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011601666","repostId":1126755850,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011121947,"gmtCreate":1648830817419,"gmtModify":1676534407295,"author":{"id":"4100143081992750","authorId":"4100143081992750","name":"fhho32","avatar":"https://community-static.tradeup.com/news/2e9d1fc00d659255c125be74d13236ea","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011121947","repostId":1126755850,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011113738,"gmtCreate":1648826946268,"gmtModify":1676534406506,"author":{"id":"4110175785559852","authorId":"4110175785559852","name":"BenjiFuji","avatar":"https://community-static.tradeup.com/news/330f59d829009a2c318784ab2b5e6098","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":0},"htmlText":"Still a long way to go after phase 1...&nbsp;","listText":"Still a long way to go after phase 1...&nbsp;","text":"Still a long way to go after phase 1...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011113738","repostId":1126755850,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":180,"commentSize":19,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126755850"}